CVS Health Issues $4 Billion in Senior Notes

CVS Health ( (CVS) ) has shared an announcement.

On August 11, 2025, CVS Health Corporation entered into an Underwriting Agreement to issue and sell $4 billion in senior notes with varying maturity dates and interest rates, including 5.000% Senior Notes due 2032 and 6.250% Senior Notes due 2065. The issuance, completed on August 15, 2025, is expected to yield net proceeds of approximately $3.96 billion, which may impact the company’s financial strategy and market positioning by potentially enhancing its capital structure.

The most recent analyst rating on (CVS) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on CVS Health stock, see the CVS Stock Forecast page.

Spark’s Take on CVS Stock

According to Spark, TipRanks’ AI Analyst, CVS is a Outperform.

CVS Health’s overall stock score is driven by strong financial performance and a positive outlook from the latest earnings call. The company’s solid revenue growth and effective cash management are significant strengths, while profitability margins and return on equity present areas for improvement. Technical indicators suggest neutral momentum, and the valuation is fair with an attractive dividend yield. Challenges in healthcare delivery and Group Medicare Advantage are noted but are balanced by growth initiatives.

To see Spark’s full report on CVS stock, click here.

More about CVS Health

CVS Health Corporation operates in the healthcare industry, providing a wide range of services including pharmacy benefits management, retail pharmacy, and healthcare services. The company focuses on improving healthcare access and affordability, positioning itself as a leader in the integrated healthcare services market.

Average Trading Volume: 7,791,856

Technical Sentiment Signal: Buy

Current Market Cap: $84.64B

Find detailed analytics on CVS stock on TipRanks’ Stock Analysis page.